Latest News for PharmaRoth Labs Stock (OTC:ROTH)

PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

News

Intraday Update

Markets

Movers

Trading Ideas

AACAY

AAPL

AAVVF

ACLS

AFGC

AIMT

AINV

ALAC

ALLE

ALPMY

AMCI

AMED

ARES

ASMIY

ASML

ASPN

ATKR

ATLKY

BABA

BANF

BNTX

BVSN

BXLC

BXMT

CALB

CBRE

CBSH

CDAY

CDUAF

CIFAF

CKOCF

CMRE

CPWHF

CRUS

CSXXY

DOCU

DSDVY

DTIL

EPZM

EQUEY

Eaton Vance Tax-Advantaged Global Dividend

FBHS

FBNC

FCNCA

FELE

FRPT

FTAI

FTLF

GBERY

GLPG

GMED

GNGBY

GNRC

GOLF

GOOG

GOOGL

HARP

HBAN

Stocks That Hit 52-Week Highs On Friday

PHARMAROTH LABS INC by PharmaRoth Labs, Inc.

PharmaRoth Labs Inc

ROTH CH ACQUISITION CO CL A

ROTH CH ACQUISITION CO UNIT 1 COM &1/2 WT EXP

ROTHSCHILD & CO SCA ORD by ROTHSCHILD & CO SCA

ROTH CH ACQ CL A by Roth CH Acquisition Co.

Roth CH Acquisition Co

Roth CH Acquisition Co Units (1 Ord Class A & 1/2 War)

Roth CH Acquisition Co Warrants (20/10/2026)

Roth CH Acquisition V Co

Rotharium

<p>Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) in the last three months.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.9, a high estimate of $30.00, and a low estimate of $25.00. Observing a 9.41% increase, the current average has risen from the previous average price target of $25.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399304_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Avantor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Daniel Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avantor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Avantor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Avantor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Avantor's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AVTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Avantor analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Avantor</h2>
<p>Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.</p>
<h3>Unraveling the Financial Story of Avantor</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Avantor's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-4.02%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.72%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Avantor's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.9%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.76%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.05</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

AVTR

Beyond The Numbers: 10 Analysts Discuss Avantor Stock

<p><i>Data Now Available on Company Website Following 8-K Filing</i><br /><br />&nbsp;</p>
<p><i>Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures</i></p>
<p><i>Gene Expression Biomarker Data Demonstrate that Treatment with TFF TAC Leads to Normalization of Expression of Rejection-Related Genes</i></p>
<p>FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that data from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection is available on the Company's website. These data were recently presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2 study, via an oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 44th&nbsp;Annual Meeting during a late breaking clinical science abstract session on April 13, 2024. The data became available following the Company's 8-K filing.</p>
<p>"Following the presentation of these updated data from our ongoing Phase 2 study of TFF TAC at this year's ISHLT meeting, we have received highly positive feedback from the transplant medicine community, indicating heightened awareness of this innovative program and a growing enthusiasm for its potential to improve upon the current standard of care," said Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. "Looking ahead, we are focused on advancing this highly innovative program into potentially registrational testing, and we look forward to sharing additional data from the TFF TAC Phase 2 trial later this year."</p>
<p>"These unprecedented results from our Phase 2 study provide evidence that TFF TAC has the potential to optimize lung immune suppression at decreased systemic exposures. TFF TAC can prevent rejection of the transplanted lung when delivered at only one-sixth of the oral tacrolimus dose and at two-thirds of the oral tacrolimus systemic trough exposures, levels predicted to decrease systemic toxicities," said Dr. Zamaneh Mikhak, Chief Medical Officer of TFF Pharmaceuticals. "In addition, our gene expression data demonstrate that TFF TAC normalizes the expression of genes associated with lung transplant rejection in patients whose systemic exposures are decreased, providing evidence at a molecular level that treatment with TFF TAC can increase lung immune suppression at reduced systemic exposures. These data collectively point to the potential opportunity to improve efficacy as well as safety after lung transplantation with TFF TAC."</p>


Biotech

General

TFFP

TFF Pharmaceuticals Makes Available Phase 2 Data From Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection Presented At The Recent ISHLT Annual Meeting

<p>Deep-pocketed investors have adopted a bullish approach towards Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SQ usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Block. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 40% bearish. Among these notable options, 3 are puts, totaling $384,780, and 7 are calls, amounting to $368,741.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $100.0 for Block, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Block's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Block's substantial trades, within a strike price spectrum from $65.0 to $100.0 over the preceding 30 days.</p>
<h3>Block Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399301_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$4.1</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$75.00</td>
<td>$235.3K</td>
<td>496</td>
<td style="text-align: right;">14</td>
</tr>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.35</td>
<td>$8.35</td>
<td>$65.00</td>
<td>$107.7K</td>
<td>302</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.44</td>
<td>$1.4</td>
<td>$1.44</td>
<td>$87.50</td>
<td>$88.9K</td>
<td>2.2K</td>
<td style="text-align: right;">645</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/31/24</td>
<td>$1.49</td>
<td>$1.29</td>
<td>$1.5</td>
<td>$90.00</td>
<td>$75.0K</td>
<td>28</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$1.39</td>
<td>$1.38</td>
<td>$1.39</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>1.3K</td>
<td style="text-align: right;">852</td>
</tr>
</tbody>
</table>
</p>
<h3>About Block</h3>
<p>Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.</p>
<p>Following our analysis of the options activities associated with Block, we pivot to a closer look at the company's own performance.</p>
<h3>Block's Current Market Status</h3>
<ul>
<li>With a volume of 688,551, the price of SQ is up 0.23% at $74.65. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 3 days.</li>
</ul>
<h3>Expert Opinions on Block</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $92.6.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Block with a target price of $98. </li>
<li>An analyst from Susquehanna persists with their Positive rating on Block, maintaining a target price of $100. </li>
<li>Maintaining their stance, an analyst from Mizuho continues to hold a Buy rating for Block, targeting a price of $106. </li>
<li>Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Underweight with a new price target of $60.</li>
<li>An analyst from Benchmark persists with their Buy rating on Block, maintaining a target price of $99. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Block with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Smart Money Is Betting Big In Block Options

<p>Financial giants have made a conspicuous bullish move on GE Aero. Our analysis of options history for GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 61% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $117,870, and 10 were calls, valued at $962,504.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $120.0 to $230.0 for GE Aero during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of GE Aero stands at 602.25, with a total volume reaching 2,546.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in GE Aero, situated within the strike price corridor from $120.0 to $230.0, throughout the last 30 days.</p>
<h3>GE Aero Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399296_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$165.00</td>
<td>$218.7K</td>
<td>1.6K</td>
<td>83</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/07/24</td>
<td>$1.59</td>
<td>$1.5</td>
<td>$1.5</td>
<td>$180.00</td>
<td>$150.0K</td>
<td>103</td>
<td>1.2K</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$7.0</td>
<td>$6.2</td>
<td>$6.9</td>
<td>$157.50</td>
<td>$138.0K</td>
<td>852</td>
<td>200</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/24/24</td>
<td>$45.65</td>
<td>$45.25</td>
<td>$45.65</td>
<td>$120.00</td>
<td>$132.3K</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$29.55</td>
<td>$27.2</td>
<td>$28.11</td>
<td>$160.00</td>
<td>$87.0K</td>
<td>457</td>
<td>30</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Aero</h3>
<p>GE Aerospace is the global leader in designing, manufacturing, and servicing large aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000. GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.</p>
<p>After a thorough review of the options trading surrounding GE Aero, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>GE Aero's Current Market Status</h3>
<ul>
<li>Trading volume stands at 602,952, with GE's price up by 1.48%, positioned at $164.76.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for GE Aero</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $176.2.</p>
<ul>
<li>An analyst from Citigroup has decided to maintain their Buy rating on GE Aero, which currently sits at a price target of $186. </li>
<li>An analyst from RBC Capital has decided to maintain their Outperform rating on GE Aero, which currently sits at a price target of $160. </li>
<li>An analyst from Argus Research has decided to maintain their Buy rating on GE Aero, which currently sits at a price target of $180. </li>
<li>Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on GE Aero with a target price of $165. </li>
<li>An analyst from Deutsche Bank has decided to maintain their Buy rating on GE Aero, which currently sits at a price target of $190. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for GE Aero, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of GE Aero's Latest Options Trends

<p>Financial giants have made a conspicuous bullish move on Citigroup. Our analysis of options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 75% of traders were bullish, while 0% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $4,538,400, and 10 were calls, valued at $631,131.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $75.0 for Citigroup during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Citigroup's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Citigroup's significant trades, within a strike price range of $50.0 to $75.0, over the past month.</p>
<h3>Citigroup Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399290_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/03/24</td>
<td>$12.6</td>
<td>$11.25</td>
<td>$12.0</td>
<td>$75.00</td>
<td>$3.6M</td>
<td>0</td>
<td>3.0K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$60.00</td>
<td>$938.4K</td>
<td>546</td>
<td>3.0K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$1.54</td>
<td>$1.5</td>
<td>$1.54</td>
<td>$62.00</td>
<td>$77.1K</td>
<td>9.2K</td>
<td>3.0K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$1.53</td>
<td>$1.49</td>
<td>$1.52</td>
<td>$62.00</td>
<td>$76.0K</td>
<td>9.2K</td>
<td>3.5K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$1.44</td>
<td>$1.4</td>
<td>$1.43</td>
<td>$62.00</td>
<td>$71.5K</td>
<td>9.2K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>In light of the recent options history for Citigroup, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Citigroup</h3>
<ul>
<li>With a trading volume of 734,961, the price of C is up by 0.35%, reaching $62.88.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Citigroup with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With Citigroup

<p>Ratings for Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $50.33, with a high estimate of $53.00 and a low estimate of $47.00. A decline of 0.83% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399288_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Gaming and Leisure Props is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$53.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gaming and Leisure Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gaming and Leisure Props compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Gaming and Leisure Props's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Gaming and Leisure Props's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GLPI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Gaming and Leisure Props analyst ratings.</strong></a></p>
<h2>Delving into Gaming and Leisure Props's Background</h2>
<p>Gaming and Leisure Properties Inc, or GLP, is a real estate investment property trust whose primary business consists of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The GLPI's portfolio consisted of interests in sixty one gaming and related facilities, the real property associated with thirty four gaming and related facilities operated by PENN, the real property associated with six gaming and related facilities operated by Caesars Entertainment Corporation.</p>
<h3>Breaking Down Gaming and Leisure Props's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Gaming and Leisure Props's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>5.84%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Gaming and Leisure Props's net margin excels beyond industry benchmarks, reaching <strong>46.38%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Gaming and Leisure Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.21%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Gaming and Leisure Props's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.48%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Gaming and Leisure Props's debt-to-equity ratio is below the industry average. With a ratio of <b>1.67</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GLPI

Critical Insights From Gaming and Leisure Props Analyst Ratings: What You Need To Know

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $131.89, a high estimate of $190.00, and a low estimate of $103.00. This current average has increased by 6.52% from the previous average price target of $123.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399281_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$111.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axsome Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Axsome Therapeutics analyst ratings.</strong></a></p>
<h2>Get to Know Axsome Therapeutics Better</h2>
<p>Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.</p>
<h3>Axsome Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of <strong>193.5%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-137.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-42.85%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Axsome Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-16.59%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Axsome Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.98</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AXSM

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

<p><i>Romil Bahl to step down and Ronald Totton named as Interim President and CEO</i></p>
<p>ATLANTA, April 29, 2024 /PRNewswire/ -- KORE Group Holdings, Inc. <strong>(NYSE:</strong><a href="https://www.benzinga.com/stock/KORE#NYSE"><strong>KORE</strong></a><strong>)</strong> ("KORE," the "Company," "we" or "our"), a global leader in Internet of Things ("IoT") Solutions and pioneering IoT hyperscaler, and provider of IoT Connectivity, Solutions and Analytics, announced today that Romil Bahl will be stepping down as President and Chief Executive Officer and that the Company's Board of Directors (the "Board") has named Ronald Totton as the Company's Interim President and Chief Executive Officer, effective May 3, 2024.</p>
<p>Romil Bahl has served as KORE's President and CEO since 2017.&nbsp; He has led the KORE 3.0 Vision and Growth Strategy that has enabled the Company to triple the number of IoT Connected Devices it supports globally, expanded its portfolio of services, and guided KORE to five consecutive years in the Gartner Leaders quadrant for IoT-managed services. Mr. Bahl also led the transformation of the Company resulting in KORE's listing on the New York Stock Exchange. In mutual agreement with the Board, he will transition from his role as President and CEO on May 3, 2024.</p>
<p>"Romil has been a fantastic leader for us," said Tim Donahue, Chairman of the Board. "From our first meeting back in 2020, I have had the utmost respect for Romil's work ethic and integrity, his strategic thinking, and his focus on the customer value proposition."</p>
<p>"It has been an honor and a privilege to lead KORE over the last six and a half years," said Mr. Bahl. &nbsp;"I would like to thank our global team of IoTers, without whom none of our successes would have been possible. KORE is now well positioned for the Decade of IoT, with an industry-leading eSIM proposition, pre-configured solutions in health, fleet, and high bandwidth applications, and a one-stop shop of services that help simplify IoT deployments."</p>
<p>Mr. Totton, who will succeed Mr. Bahl, brings nearly three decades of strategy, finance, sales, and leadership experience to the President and CEO role at KORE, including many years in the Technology, Media, and Telecoms sector. Prior to joining KORE, Mr. Totton served as Chief Executive Officer of ST Telemedia Cloud (Temasek Holdings) and Executive Vice President, Corporate Development at ST Telemedia Group. &nbsp;He previously held leadership roles at BT Global Services, including Chief Executive Officer, Northern, Central and Eastern Europe, and Russia as well as Managing Director, South East Asia.&nbsp; In addition to his executive roles, Totton held a number of Directorship roles for both ST Telemedia Group and BT Global Services.</p>
<p>"Ron is an accomplished executive in the telecom sector and beyond," said Mr. Donahue. "He has a track record of leading innovative businesses toward growth and transformation, and he will serve KORE's stakeholders well. We are very fortunate to have a leader of Ron's caliber join the KORE team."</p>
<p>Mr. Totton stated, "KORE has long been recognized as a pioneer in the IoT space – an innovative and flexible partner that creates meaningful impact for customers. &nbsp;KORE's next chapter builds on this foundation to even better serve our customers and deliver enhanced value for stockholders.&nbsp; There are incredible opportunities ahead for the company and this team." &nbsp;Mr. Totton today joins the Company as an executive advisor until May 3, 2024, when he will assume the role of interim President and CEO.</p>
<p>KORE's management change is not the result of any material or unexpected financial events.</p>


Management

KORE

KORE Announces President And CEO Transition; Romil Bahl To Step Down And Ronald Totton Named As Interim President And CEO, Effective May 3, 2024

<p>Throughout the last three months, 12 analysts have evaluated ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $145.58, a high estimate of $170.00, and a low estimate of $120.00. This upward trend is evident, with the current average reflecting a 4.73% increase from the previous average price target of $139.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399240_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive ConocoPhillips. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$154.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$158.00</td>
<td>-</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$139.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ConocoPhillips. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ConocoPhillips compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of ConocoPhillips's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into ConocoPhillips's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ConocoPhillips analyst ratings.</strong></a></p>
<h2>About ConocoPhillips</h2>
<p>ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.</p>
<h3>ConocoPhillips's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, ConocoPhillips faced challenges, resulting in a decline of approximately <strong>-20.63%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> ConocoPhillips's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>20.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ConocoPhillips's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>6.13%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> ConocoPhillips's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>3.14%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> ConocoPhillips's debt-to-equity ratio is below the industry average at <strong>0.38</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 12 Analyst Evaluations For ConocoPhillips

<p>Stifel  analyst W. Andrew Carter   maintains Pool (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) with a Hold and lowers the price target from $370 to $360.</p>


Price Target

POOL

Stifel Maintains Hold on Pool, Lowers Price Target to $360

<p>Throughout the last three months, 5 analysts have evaluated Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $129.4, a high estimate of $152.00, and a low estimate of $106.00. This current average reflects an increase of 23.47% from the previous average price target of $104.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399228_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Mohawk Industries among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$122.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$106.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Joe Ahlersmeyer</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$98.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mohawk Industries. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mohawk Industries compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Mohawk Industries's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MHK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Mohawk Industries analyst ratings.</strong></a></p>
<h2>All You Need to Know About Mohawk Industries</h2>
<p>Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States.</p>
<h3>Breaking Down Mohawk Industries's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Mohawk Industries faced challenges, resulting in a decline of approximately <strong>-1.45%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Mohawk Industries's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>5.34%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Mohawk Industries's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.87%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.04%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Mohawk Industries's debt-to-equity ratio is below the industry average at <strong>0.41</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Mohawk Industries

<p>Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) has outperformed the market over the past 10 years by 7.1% on an annualized basis producing an average annual return of 17.65%. Currently, Lowe's Companies has a market capitalization of $132.00 billion. </p>
<p><strong>Buying $1000 In LOW:</strong> If an investor had bought $1000 of LOW stock 10 years ago, it would be worth <strong>$4,982.93</strong> today based on a price of $230.69 for LOW at the time of writing.</p>
<h3>Lowe's Companies's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399225_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Lowe's Companies 10 Years Ago Would Be Worth This Much Today

<p>Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has outperformed the market over the past 5 years by 18.91% on an annualized basis producing an average annual return of 30.52%. Currently, Arista Networks has a market capitalization of $82.69 billion. </p>
<p><strong>Buying $1000 In ANET:</strong> If an investor had bought $1000 of ANET stock 5 years ago, it would be worth <strong>$3,392.83</strong> today based on a price of $263.67 for ANET at the time of writing.</p>
<h3>Arista Networks's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399220_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ANET

$1000 Invested In Arista Networks 5 Years Ago Would Be Worth This Much Today

<p>4 analysts have expressed a variety of opinions on XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated XOMA and provided 12-month price targets. The average target is $65.5, accompanied by a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 11.49% decrease from the previous average price target of $74.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399219_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of XOMA by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Zhuang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to XOMA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of XOMA compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of XOMA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of XOMA's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on XOMA analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind XOMA</h2>
<p>XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.</p>
<h3>Financial Insights: XOMA</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> XOMA displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>23.35%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> XOMA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1171.69%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-22.07%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-11.99%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> XOMA's debt-to-equity ratio surpasses industry norms, standing at <strong>1.4</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


XOMA

Cracking The Code: Understanding Analyst Reviews For XOMA

<p>Stifel  analyst Vincent Anderson   maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Buy and raises the price target from $68 to $69.</p>


Stifel Maintains Buy on Olin, Raises Price Target to $69

<p>RBC Capital  analyst Brad Heffern   maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Outperform and lowers the price target from $49 to $47.</p>


RBC Capital Maintains Outperform on Gaming and Leisure Props, Lowers Price Target to $47

<p>A South Korean woman was deceived into transferring $50,000 to a scammer impersonating <a href="https://www.benzinga.com/real-estate/24/04/38409088/elon-musks-tesla-sidesteps-austin-in-a-bold-move-to-de-annex-2-100-acres-under-controversial-texas-s">Elon Musk</a> through advanced deepfake technology.&nbsp;</p>
<p>The scam, which involved artificial intelligence (AI)-generated photos and a deepfake video call, highlights the growing menace of technology-facilitated fraud.</p>
<p>The victim, referred to by the pseudonym Jeong Ji-sun, encountered the impersonator on Instagram in July 2023. According to Ji-sun, the scammer provided AI-generated images of what appeared to be Musk's ID card and him at work, which gradually convinced her of the authenticity of the person she was communicating with.&nbsp;</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<p>"Although I have been a huge fan of Musk after reading his biography, I doubted it at first," Ji-sun told The Korea Herald. "‘Musk' sent me his ID card and a photo of him at work. He also explained that he contacts fans randomly."</p>
<p>The deception deepened with a video call where the fake Musk confessed his love for Ji-sun, further manipulating her emotions.&nbsp;</p>
<p>"Musk' even said ‘I love you, you know that?' when we made a video call," Ji-sun said.&nbsp;</p>
<p>Convinced she was dealing with the real Musk, Ji-sun was persuaded to transfer 70 million Korean won ($50,000) to a bank account she was told was that of Musk's Korean employee. The scammer promised lucrative returns on her investment, leveraging her trust to commit the fraud.&nbsp;</p>
<p><strong>Trending:</strong></p>
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
<p>The case is part of a disturbing trend observed globally. In 2022, the Federal Trade Commission reported that romance scams had cost victims $1.3 billion. The emergence of AI and deepfake technology is compounding the challenge, making it difficult to verify identities on social media and dating platforms. The FBI has also highlighted a significant rise in deepfake-related criminal activities, emphasizing the urgent need for awareness and technological safeguards against such sophisticated scams. It is crucial to remain vigilant and verify the sources of digital content to prevent falling prey to deceptive practices.</p>
<p>According to Norton, you can identify a deepfake by looking for certain visual discrepancies: abnormal skin tones, discoloration, unusual lighting and misplaced shadows can all indicate that an image may be fabricated. Hair that appears too perfect, lacking frizz or flyaways, suggests that the image might not accurately capture these intricate details, pointing to the use of artificial generation.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>


Real Estate

A Woman Loses $50,000 Thinking Elon Musk Was Telling Her 'I Love You' And Wanted To Make Her Rich — But It Was An Elaborate Deepfake Scam

<p>Wells Fargo  analyst Larry Biegelsen   upgrades Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) from Equal-Weight to Overweight and raises the price target from $21 to $45.</p>


Upgrades

TNDM

Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $45

<p>Stifel  analyst Mark Astrachan   maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Buy and lowers the price target from $65 to $63.</p>


MNST

Stifel Maintains Buy on Monster Beverage, Lowers Price Target to $63

<p>Argus Research  analyst Jim Kelleher   maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $68 to $88.</p>


Argus Research Maintains Buy on Western Digital, Raises Price Target to $88

PharmaRoth Labs

AACAF

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAF

ALFVY

ALIAF

ALIF

ALIZF

ALLVF

ALMTF

ALSMY

ALVOF

ALYI

AMADY

AMAZ

Stocks That Hit 52-Week Highs On Tuesday

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for PharmaRoth Labs Stock (OTC:ROTH)

Tuesday, March 24, 2020

Friday, December 06, 2019